Companies in #Multidrug-Resistant Infections
Found 1 company operating in this sector.
Spero Therapeutics is a clinical-stage biopharmaceutical company developing novel treatments for rare diseases and multidrug-resistant (MDR) bacterial infections. Its lead asset Utebzi (tebipenem pivoxil HBr), an oral carbapenem co-developed with GSK, was FDA-approved in June 2026 for complicated urinary tract infections.